About
About ARCA Biopharma Inc
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Visit company website
5 years, 4 months ago
ARCA biopharma, Inc is currently in a long term downtrend where the price is trading 14.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
ARCA biopharma, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 318.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 159.3% to $-3M since the same quarter in the previous year.
Based on the above factors, ARCA biopharma, Inc gets an overall score of 1/5.